Adage Capital Partners GP L.L.C. Acquires 7,175 Shares of DexCom, Inc. (NASDAQ:DXCM)

Adage Capital Partners GP L.L.C. boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 555,121 shares of the medical device company's stock after purchasing an additional 7,175 shares during the period. Adage Capital Partners GP L.L.C. owned about 0.14% of DexCom worth $43,172,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Forvis Mazars Wealth Advisors LLC increased its stake in DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after buying an additional 118 shares during the period. Principal Securities Inc. lifted its stake in DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after buying an additional 135 shares during the last quarter. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares during the period. Level Four Advisory Services LLC grew its holdings in DexCom by 1.1% in the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after buying an additional 150 shares in the last quarter. Finally, Covestor Ltd increased its holdings in shares of DexCom by 15.6% during the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock valued at $86,000 after purchasing an additional 150 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Down 0.7 %

DXCM stock traded down $0.48 during midday trading on Monday, reaching $71.18. The company had a trading volume of 2,782,702 shares, compared to its average volume of 4,213,895. The company has a 50 day moving average of $73.09 and a two-hundred day moving average of $76.73. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26. The company has a market capitalization of $27.91 billion, a P/E ratio of 49.78, a PEG ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research reports. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Mizuho started coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price on the stock. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Finally, Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $99.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.